DARZALEX
Daratumumab
- Strength
- 100 mg/5mL
- Form
- Injection, Solution, Concentrate
- Class
- CD38-directed Cytolytic Antibody
Janssen Biotech, Inc.
Not stocked by us — reference only
daratumumab and hyaluronidase-fihj (human recombinant)
Listed by Janssen Biotech, Inc.
This is a combination product. It is not interchangeable with a single-ingredient medicine containing only one of these.
| Dosage form | Injection |
|---|---|
| Route | Subcutaneous |
| Drug class | CD38-directed Cytolytic Antibody; Endoglycosidase |
| Approval route | BLA — biologic licence |
| NDC code | 57894-503 |
| FDA application | BLA761145 |
| RxNorm concept | 2375136 |
| Package sizes listed | 1 |
| Marketed since | May 2020 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Daratumumab
Janssen Biotech, Inc.
Not stocked by us — reference only
Daratumumab
Janssen Biotech, Inc.
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.